Pancreatic cancer is the 4th most common cause of cancer-related mortality in the Western world. Pancreatic ductal adenocarcinoma (PDAC) is usually diagnosed at a later stage and mechanisms of growth and progression have yet to be clarified. Treatment fails mostly due to chemo- and radiation resistance. In order to overcome this issue, nanomedicine has become an opportunity for new diagnostic and therapeutic approaches, providing a tool to enhance drug delivery to treat PDAC. It allows the development of a nanoparticle-based drug delivery system (DDS) that combines several chemotherapeutic agents with nanocarriers for PDAC management. In this review, we describe the latest therapies and advances in pharmaceutical nanoformulations for PDAC management.
Received Date: 2021-09-10